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Postmortem samples from 14 cases of suspected heroin overdose
were subjected to a preliminary systematic toxicological analysis in
order to highlight the presence of unknown exogenous compounds
(e.g., drugs of abuse, alcohol) that may have played a role in the
mechanism of death. This analysis unveiled histories of poly-drug
use in seven of the cases under investigation. Moreover, the concen-
trations of morphine and codeine in the brain were also investigated,
and the results were compared with the data obtained from the blood
specimens. The concentration of morphine in blood ranged from 33 to
688 ng/mL, while the concentration of codeine ranged from 0 to
193 ng/mL. However, in the brain, the concentration of morphine
was found to be between 85 and 396 ng/g, while the levels of co-
deine ranged from 11 to 160 ng/g. The codeine/morphine ratio in
the blood ranged from 0.043 to 0.619; however, in the brain, the
same ratio was found to be between 0.129 and 0.552. In most
cases, a significantly higher codeine/morphine ratio was found in
the brain, suggesting the accumulation of codeine in brain tissue
due its high lipophilicity as compared with morphine.
Introduction
The detection of heroin in the biological ﬂuids of consumers is
difﬁcult due to its short half-life (2–6 min after intravenous
injection) (1). In the body, it is rapidly hydrolyzed to
6-monoacetylmorphine (6-MAM), which in turn is converted
into morphine. Subsequently, morphine is conjugated with glu-
curonic acid to give mainly morphine-3-b-D-glucuronide and
morphine-6-b-D-glucuronide (1, 2).
Consequently, the blood concentration of morphine is used as
an important analytical marker to establish the cause of death in
cases of suspected heroin overdose (2–4). However, some over-
dose fatalities show relatively low blood concentrations of mor-
phine, i.e., below or similar to the levels found in long-term
heroin consumers or intoxicated users (5). This could be due
to a variety of reasons, such as the relationship between the lethal
dose and the individual’s tolerance (5–8), the complex nature of
heroin metabolism, the presence of systemic dysfunction (5, 7)
and the concurrent use of other drugs or substances of abuse
(1, 6, 9, 10), particularly alcohol (11). Moreover, postmortem re-
distribution or drug instability can affect the concentration of
substances detected in blood after death (12–14).
In our laboratory, postmortem samples are routinely subjected
to a systematic toxicological analysis (STA) in order to highlight
the presence of unknown exogenous compounds (e.g., drugs of
abuse, alcohol) that may have played a role in the mechanism of
death. With regard to alcohol, the blood alcohol concentration
(BAC; g/dL) is also taken into account in our STA, as suggested
by Polettini et al. (11), who demonstrated that pharmacokinetic
interactions between heroin and alcohol occur when individuals
are exposed to high doses of these substances.
In cases in which STA suggests the presence of heroin metabo-
lites, brain specimens are also typically analyzed (2, 15). From
these previous analyses, the sites of action of heroin and its
main metabolites have been identiﬁed, and they are considered
to be primarily located in the central nervous system (CNS). It
has also been established that the concentrations of heroin meta-
bolites measured in postmortem brain samples are close or equal
to the levels responsible for the toxic effects that result in death.
Compared with blood and other tissues, the analysis of brain sam-
ples has some advantages. For example, the brain is compartmen-
talized by the blood–brain barrier and is therefore characterized
by delayed degradation of toxic substances as well as delayed bac-
terial transmigration. In addition, it has a lower intrinsic metabol-
ic activity and is less prone to postmortem redistribution. On the
other hand, the brain represents a complex matrix and analysis
can be complicated.
Most methods for the analysis of brain specimens were pub-
lished in the 1980s, when large sample quantities were needed
due to the lack of sensitivity of the analytical techniques.
However, in recent years, there has been an improvement in sam-
ple preparation, automation and detection, which has permitted
the collection of reference data (13).
In our previous study (16), we developed a gas chromatog-
raphy/mass spectrometry (GC/MS) method to investigate the
brain distribution patterns of heroin metabolites and impurities
(morphine and codeine). The method resulted in good recovery
of analytes and elimination of interfering species thanks to a sam-
ple pretreatment step, which was introduced prior to solid-phase
extraction (SPE). After validation, the method was applied to the
analysis of samples from six brain areas (hippocampus, frontal
lobe, occipital lobe, nuclei, bulb and pons) from two possible
cases of heroin-related deaths. No evidence of accumulation of
heroin metabolites in speciﬁc brain regions was obtained (16).
As a consequence, the current study focuses on the use of our
validated method for the determination of morphine and co-
deine levels in nuclei specimens from 14 fatal cases of suspected
heroin overdose. The results of this analysis were subsequently
compared with metabolite levels in the blood (from STA),




Postmortem samples, which were supplied by the Institute of
Legal Medicine and Assurance at the University of Palermo,
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were collected from 14 deceased patients (Table I). The subjects
were men aged between 23 and 45 years, and circumstantial evi-
dence suggested that the deaths in each case were heroin
related.
All autopsies performed at the Institute of Legal Medicine and
Assurance at the University of Palermo were reviewed, and the
autopsy documentation, including the charts, ﬁnal reports and
circumstances surrounding each death, was recorded.
Tissue samples from each organ were routinely collected from
the subjects during the autopsy and stained with hematoxylin
and eosin for histological assessment. During the overall examin-
ation of each subject, the cause of death could not be conclusively
determined. In most cases, arteriosclerosis and myocardial
hypertrophy were excluded, and toxicological analysis was sub-
sequently used to determine the cause of death.
Preliminary screening of the samples was carried out, followed
by STA, including volatile organic compound (VOC) analysis and
quantitative GC determination of the heroin metabolites.
Chemicals and reagents
Morphine, codeine and nalorphine (internal standard, IS) were
purchased from S.A.L.A.R.S. (Italy). Methanol of analytical grade,
5-sulfosalicylic acid dihydrate, trichloroacetic acid and zinc sul-
fate were obtained from Sigma–Aldrich (Germany). Toluene, so-
dium tetraborate/hydrochloric acid (pH 9) buffer solution and
N-methyl-N-(trimethylsilyl)-triﬂuoroacetamide (MSTFA) were
purchased from Fluka (Switzerland), and dichloromethane and
isopropyl alcohol were obtained from Prolabo (Italy).
Ammonium sulfate was supplied by Carlo Erba (Italy), as well
as glacial acetic acid. Water (18.2 mV cm21) was obtained
using a Milli-Q puriﬁcation system (Millipore, France). All
reagents were of analytical grade and stored according to the
manufacturer’s instructions.
Systematic and toxicological analysis
As a part of the STA protocol, sample screening and SPE were fol-
lowed by GC–MS analysis. These methods are typically applied to
blood, urine and bile specimens, and allow the detection and
quantitative determination of the main metabolites of heroin,
i.e., morphine and, where detectable, 6-MAM. In addition to
these metabolites, impurities and ‘cutting agents’ (inexpensive
chemicals used to dilute illicit drugs), which tend to be present
in ‘street heroin’, were also detected; for example, acetylcodeine
and its metabolite codeine, paracetamol and caffeine were com-
monly found. To establish the ‘total’ amount of morphine (and
the ‘total’ amount of codeine) in the urine and bile samples, a
chemical hydrolysis procedure was adopted prior to SPE.
Head space-gas chromatography/ﬂame ionization detector
(HS-GC/FID) analysis was performed on blood samples to deter-
mine the presence of VOCs, with particular reference to ethanol.
Where available, femoral blood samples were used, as these sam-
ples tend to exhibit less pronounced postmortem diffusion phe-
nomena, which may affect the accuracy of the measurements.
Screening
When urine samples were available, sample screening was initially
performed (Table II) by applying a small volume of the specimen
onto a commercial device (RapidTest d.a.u.w10, Siemens). This
very simple test provides a qualitative screen for the presence
of four classes of compounds, which are related to the following:
(i) Methamphetamine (cutoff: 1,000 ng/mL)
(ii) Morphine (cutoff: 300 ng/mL)
(iii) Cocaine and benzoylecgonine (cutoff: 300 ng/mL)
(iv) 11-Nor-D9-tetrahydrocannabinol (cutoff: 50 ng/mL)
(v) Phencyclidine (cutoff: 25 ng/mL)
(vi) Oxazepam (cutoff: 300 ng/mL)
(vii) Secobarbital (cutoff: 300 ng/mL)
(viii) Methadone (cutoff: 300 ng/mL)
(ix) Nortriptyline (cutoff: 1000 ng/mL)
(x) D-Amphetamine (cutoff: 1000 ng/mL)
Generic investigation for the detection of basic compounds
All the available biological ﬂuids were analyzed by GC–MS from a
qualitative point of view, i.e., molecules were identiﬁed via
known retention times and mass spectra. If a drug of abuse
and/or its metabolites and/or other exogenous compounds
were detected, a further GC–MS analysis was performed for
quantitative purposes. Sample preparation (e.g., initial volume
of matrix) and instrument settings were targeted to the com-
pounds of interest, and working standard samples, i.e., blank bio-
logical ﬂuids spiked with standard solutions of the most common
drugs of abuse and their metabolites (total amount: 1 mg), were
analyzed together with the unknown specimens. The quantiﬁca-
tion procedure was typically applied to methadone and its main
metabolites, EMDP (2-ethyl-5-methyl-3,3-diphenyl-pyrroline)
and EDDP (2-ethyl-1,5-dimethyl-3,3-diphenyl-pyrrolidine),
using proadifen as an IS; to amphetamines, methamphetamine
and 3,4-methylenedioxymethamphetamine (MDMA), using
2-phenyl-ethyl amine as an IS; to cocaine and benzoylecgonine,
using scopolamine as an IS; and to codeine, morphine, 6-MAM
and acetylcodeine, using nalorphine as an IS.
Aliquots of blood, urine or bile (between 250 mL and 2 mL de-
pending on the nature of the sample and its availability), with
50 mL IS (in methanol; concentration: 20 mg/mL), were diluted
with sodium tetraborate/hydrochloric acid (pH 9) buffer solu-
tion to a volume of 2 or 4 mL. The resulting mixtures were
Table I
An Overview of the Demographic Information and Circumstances Surrounding Death for the Cases





Gender Circumstances of death
1 35 M Occasional use of illicit drugs reported; injection sites located at
autopsy
2 23 M Found dead in bed, injection sites located at autopsy
3 40 M Found dead at home, history of drug dependence
4 24 M Found in bed, no signs of injection, white foam and blood
around the mouth and nose
5 42 M Found dead at home, history of drug addiction, injection sites
located at autopsy
6 45 M Found dead in a street in close proximity to a syringe
7 36 M Found dead in a street, injection sites located at autopsy
8 41 M Found dead in a car
9 35 M Received methadone as treatment for heroin dependence
10 45 M Found dead in a toilet in close proximity to a syringe
11 44 M Found dead at home with a syringe in the arm
12 31 M Found dead in a toilet with a syringe in the arm
13 42 M Found dead at home, history of drug dependence
14 35 M Found dead in a toilet in close proximity to a syringe
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centrifuged (3,500 rpm, 10 min) and the resulting supernatant
loaded (1–2 mL/min) onto Bond Elut Certify extraction car-
tridges (mixed-mode cartridges packed with non-polar C8 and
a strong anion exchange SAX sorbent; Agilent), which were pre-
viously conditioned with methanol (2 mL) and water (2 mL).
Each cartridge was then washed with water (2 mL) and 1 M acet-
ic acid (3 mL), and desiccated for 5 min before washing with
0.5 mL methanol. The cartridge was then dried in vacuo for
1 min, and the analytes subsequently eluted twice with a freshly
prepared mixture of dichloromethane, isopropanol and 30%
ammonium hydroxide (8/2/0.2, v/v/v; 1 mL). The solvent was
evaporated, and the resulting residue was dissolved in methanol
(50 mL). After drying, the sample was derivatized via the addition
of a mixture of MSTFA in toluene (1/4, v/v; 50 mL) and heating at
708C for 30 min. GC–MS analysis was then performed.
Generic investigation for the detection of acidic compounds
Aliquots of blood, urine or bile (between 250 mL and 2 mL
depending on the nature of the sample and its availability),
with 50 mL IS (hepta-barbital, 50 mg mL21 in methanol), were
diluted with sodium tetraborate/hydrochloric acid (pH 9) buffer
solution to a volume of 2 or 4 mL. The subsequent mixtures were
subjected to SPE, as described above; however, in this case, the
analytes were eluted with a freshly prepared mixture of acet-
one–chloroform (1:1, v/v; 4 mL). The solvent was evaporated,
and the residue analyzed by GC–MS after being dissolved in
methanol (50 mL) and then derivatized with 20 mL MethElut re-
agent in methanol (Thermo Scientiﬁc, Rockford, IL, USA).
Hydrolysis of morphine and codeine glucuronides in urine
and bile samples
Aliquots of urine or bile (from 200 mL to 1 mL depending on the
availability of the sample) were diluted with water to a volume of
2 mL. To this, 6 N hydrochloric acid (1 mL) and the appropriate
premixed IS (20 mg/mL) were added. Each sample was then
heated to 1008C in a water bath under pressure for 30 min.
After cooling, 30% ammonium hydroxide (550 mL) was added.
After several minutes, 2 mL pH 9 buffer was also added, and
the pH was adjusted to 8.0–8.5 with 30% ammonium hydroxide.
The samples were then subjected to SPE and analyzed as
described above.
Determination of VOCs by HS-GC
HS-GC analyses were carried out on an Ultra Thermo Electron
Trace GC (Thermo Fisher, Waltham, MA, USA) with a split–split-
less injection system and an HS 2000 Thermo Electron autosam-
pler, coupled with an FID. The system was managed by the
Thermo Electron Chrom-Card 2.3 software. The GC machine
was equipped with a VF-624 ms capillary column (30 m 
0.25 mm ID, thickness: 0.25 mm). The GC-FID system was oper-
ated under the following conditions: 50–1508C, 108C/min; ﬁnal
isotherm: 3 min; temperature: inlet 1508C, detector: 2508C; split
ﬂow: 30 mL/min; split ratio: 15; carrier constant ﬂow: 1.3 mL/
min (helium); detector gas ﬂow: 35 mL/min (hydrogen),
350 mL/min (air); makeup gas (helium): 30 mL/min; signal
range: 1; HS autosampler syringe temperature: 608C; HS autosam-
pler incubation temperature: 808C with alternate stirring; HS
autosampler incubation time: 30 min; and HS autosampler injec-
tion volume: 0.5 mL. Samples were prepared by mixing 0.5 mL
water with 0.5 mL blood and a small quantity of sodium ﬂuoride
to avoid enzymatic activation, as well as the appropriate IS in pro-
panol (0.5 mL, 0.4 mL mL21).
Brain tissue sample preparation and deproteinization
Each sample was homogenized by blending or ball milling (de-
pending on the quantity of the material available) and deprotei-
nized via an ultrasonic bath using the following protocol: 500 mg
brain tissue and 50 mL IS were diluted with 4 mL water and 2 mL
Table II
Results of the STA








1 MOR Morphine 614 266 1,842 n.p.
COC Codeine 129 n.p. n.p. –
Cocaine 20 4,156 – –
BZE 2,544 117,772 – –
2 MOR Morphine 33 25,947 22,211 n.p.
COC
Codeine 10 3,974 255 –
Cocaine 20 419 756 –
BZE 10 124 n.p. –
3 MOR Morphine 97 58 200 150
Codeine 60 n.p. n.p. –
Desmethyl
diazepam
1,497 20 n.p. –
4 MOR Morphine 315 7,602 91,235 n.p.
COC Codeine 73 646 n.p. –
BZE n.p. 479 n.p. –
5 MOR Morphine 338 1,089
(ng/g)
– n.p.
Codeine 64 Kidney – –
6 MOR Morphine 688 99 3,765 60
COC Codeine 150 n.p. 44 –
THC Cocaine n.p. 54 n.p. –
BZE n.p. 8,000 n.p. –
7 MOR Morphine 615 161 – 200
THC Codeine 193 22 – –
8 MOR Morphine 533 35,935 43,786 n.p.
COC Codeine 23 1,744 122 –
Cocaine 75 37,798 – –
BZE 1,847 45,5896 – –
9 MOR Morphine 77 12,505 – 50
MET Codeine 6 472 – –
Methadone 890 1,395 – –
EMDP 621 2,470 – –
EDDP 719 1,810 – –
10 MOR Morphine 228 8,48 571 n.p.
Codeine 25 n.p. n.p. –
11 MOR Morphine 313 740 6,638 n.p.
Codeine 72 n.p. n.p. –
12 MOR Morphine 441 1,986 5,559 n.p.
Codeine 20 75 n.p. –
6-MAM n.q. – – –
13 MOR Morphine 130 860 620 220
Codeine Trace 50 n.p. –
14 MOR Morphine 171 140 860 130
Codeine Trace 20 300 –
6-MAM n.p. n.q. – –
For the screening test, only positive results (.cutoff ) are reported. For the blood alcohol
concentration, n.p., not present, i.e., at a concentration ,0.5 g/L. For GC–MS analysis (blood,
urine and bile); n.p., not present, i.e., below the limit of detection (LOD); n.q., not quantified due
to a lack of standard or sample; trace, above the LOD but below the lower limit of quantitation; – ,
data not available.
MOR, morphine; COC, cocaine; BZE, benzodiazepine; THC, tetrahydrocannabinol; MET, methadone;
EMDP, 2-ethyl-5-methyl-3,3-diphenyl-pyrroline; EDDP, 2-ethyl-1,5-dimethyl-3,3-diphenyl-pyrrolidine;
6-MAM, 6-monoacetylmorphine.
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pH 9 buffer solution. The resulting mixture was sonicated for
15 min at room temperature. After centrifugation (4,000 rpm,
5 min), the clear supernatant was separated and extracted via SPE.
Extraction procedure
Homogenized and deproteinized encephalic samples were cen-
trifuged (4,000 rpm, 5 min) and extracted using Bond Elut-LRC
Certify solid-phase extraction cartridges (Varian, Palo Alto, CA,
USA) with a Varian vacuum manifold (Varian, CA, USA).
Cartridges were ﬁrst conditioned with 2 mL methanol and
2 mL (pH 9) buffer solution. The supernatants resulting from
the centrifugation were loaded on to the cartridges and per-
mitted to absorb through gravity. The cartridges were then
washed with 2 mL water, 3 mL of 1 M hydrochloric acid and
0.5 mL methanol. The analytes were subsequently eluted with
2  1 mL elution solvent (dichloromethane/isopropyl alcohol/
ammonium hydroxide, 8/2/0.2, v/v/v).
Chromatography
The extracts were evaporated to dryness under a stream of nitro-
gen at 408C and derivatized with a mixture MSTFA in toluene
(1/4, v/v; 50 mL) at 708C for 30 min. GC–MS analysis was per-
formed on a GC 6890 Plus with a mass selective detector
and 6890 autosampler. Data were analyzed with the MSD
ChemStation D.03.00 software (Agilent Technologies).
Chromatographic separation was carried out on a DB-5MS inert
capillary column (30 m  0.25 mm ID, thickness 0.25 mm; J & W
Scientiﬁc, Folson, CA, USA).
The GC–MS system was operated under the following condi-
tions: injection temperature: 2808C (splitless mode; 0.25 min
splitless time); interface transfer line: 2808C; ion source: 2308C;
initial column temperature: 708C. The temperature was subse-
quently increased to 1808C at a rate of 408C/min, then to
3008C at a rate of 108C/min and held at this temperature for
5 min. Helium was used as the carrier gas at a ﬂow rate of
1.2 mL/min. MS analysis was performed in SCAN (50/550 m/z)
and SIM modewith a quadrupole mass detector operated in elec-
tron ionization mode, with a beam energy of 70 eV. The injection
volume was 1 mL.
Method validation
The speciﬁcity, accuracy, precision and linearity as well as the
limit of detection (LOD) and limit of quantitation (LOQ) were
evaluated by analyzing working standard solutions prepared
with morphine and codeine at different concentrations (10, 25,
50, 100, 250, 500 and 1000 ng) and nalorphine as an IS. In par-
ticular, working standard solutions (0.1, 0.25, 0.5, 1.0, 2.5, 5.0
and 10.0 mg mL21, 100 mL) were prepared in separate tubes
and evaporated to dryness. A blank brain sample was then
added (500 mg) and after centrifugation 4,000 rpm, 1 min),
4 mL water, 50 mL IS (4 mg/mL) and 2 mL (pH 9) buffer solution
were added.
For quantitative analysis, the following ions were assessed: m/z
371 for codeine, m/z 429 for morphine and m/z 455 for nalor-
phine. The speciﬁcity was assessed by extracting control (blank)
brain samples in each validation run. The lack of interfering peaks
at the same analyte retention times conferred acceptable selectivity.
The linearity of the response of the GC–MS analysis was
assessed for codeine and morphine by plotting drug/IS peak
area ratios versus the total amount of drug in the standard solu-
tions, with intervals of 10–1000 ng. The calibration curves gave
good correlation coefﬁcients (R2 . 0.9994) for both analytes
over the whole range.
Accuracy was expressed as the percent recovery (%REC) eval-
uated by analyzing, in triplicate, six standard morphine solutions,
ranging from 25 to 1,000 ngtot, and seven standard codeine solu-
tions, ranging from 10 to 1,000 ngtot. The averaged results were
found to be satisfactory.
The same standard solutions were analyzed, in triplicate, over
3 days (I, II and III) in order to evaluate the precision of
the method. The obtained data demonstrated adequate
reproducibility.
The LOD and LOQ were also evaluated and were found to
10 and 25 ng for morphine, respectively, and 5 and 10 ng for
codeine, respectively.
Results and Discussion
The STA results for the 14 assessed cases are reported in Table II.
As is evident, in seven of the cases, other drugs of abuse, such as
cocaine, benzodiazepines or methadone, were detected in add-
ition to heroin metabolites. In six cases, signiﬁcant concentra-
tions of ethanol were also found to be present; however, it was
difﬁcult to establish a correlation between the BAC and the mor-
phine concentration, probably because of the statistically low
number of cases considered. However, since ethanol is an
enzyme inhibitor, it is fair to assume that it may affect heroin
metabolism (11).
These data have to be taken into account when determining
the cause of death in these cases. In cases of heroin overdose,
it is useful to also evaluate the distribution of heroin metabolites
in the tissues, i.e., in the liver, kidney, lung and brain. In this study,
we analyzed brain tissue, as it is well known that heroin acts upon
the brain, and information about its brain levels following an
overdose could be used to interpret the cause of death as well
as provide additional information with regard to the tolerance
of the individual subject.
The brain is a complex matrix, making analysis complicated. In
our previous work (16), we optimized an extraction procedure
and validated an analytical method to determine morphine and
codeine levels in brain tissue. The concentration of these ana-
lytes in different areas of the brain was also evaluated in our pre-
vious work, and the results suggested that there was a
homogeneous distribution. To probe further the distribution of
heroin metabolites in brain tissue, we applied our method to
the analysis of brain samples (nuclei) from 14 fatal cases of sus-
pected heroin overdose. Moreover, in the current study, the con-
centrations of the analytes in the brain were compared with the
levels detected in blood.
Table III shows the analytical results for all 14 cases. As has
been previously reported (2–5), high variability was found
with regard to the morphine levels among the 14 blood samples.
Similarly, the codeine concentrations varied from undetectable
(below the LOD) to 193.1 ng/mL. No relationship between the
levels of the two analytes in each individual sample was found
(Figure 1). This is indeed reasonable, as the concentration of
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codeine is linked to the impurities found in ‘street heroin’ and
because more than one metabolic pathway is implicated in her-
oin metabolism.
With regard to the brain tissue samples, a wide distribution of
both the concentration of morphine and the concentration of
codeine was noted, which is in agreement with the literature
(15). In fact, a wide range of blood–brain concentration ratios
has been previously reported; for example, Kintz et al. (9) inves-
tigated the blood–brain ratios of heroin in three heroin users and
found them to be 13, 1.5 and 0.24, with tissue concentrations
ranging from 0.005 to 0.089 mg kg21 of wet brain (10). In our
study, the blood level of morphine was similar to the level in
the brain in the majority of cases (Figure 1C), which agrees
with what has been previously reported (2).
The most interesting results in our study come from the com-
parison of the codeine/morphine ratios in the blood and brain
(Table III and Figure 1). Indeed, the ratios were found to be un-
expectedly higher in the brain samples than in the blood in the
majority of cases, and this result was demonstrated to be statistic-
ally signiﬁcant by a t test, even though the number of cases was
limited (P, 0.05; t ¼ 2.6736). However, for this very reason, it is
not possible to draw any general conclusions. The higher ratio in
the brain may be due to the high lipophilicity of codeine (log P
1.39) compared with morphine (log P 0.87) (17), which may sub-
sequently lead to a low concentration of morphine in the brain
when comparedwith codeine. In only three cases (Nos. 2, 3 and 6),
the concentration of codeine in the blood was higher than it was
in the brain. Unfortunately, after analyzing the history of the sub-
jects and the circumstances surrounding their deaths, we were
unable to ﬁnd an explanation for this. However, the use of
other drugs of abuse may interfere with the accumulation and
metabolism of heroin derivatives, leading to unexpected results.
Table III
Concentration of Morphine and Codeine in Blood (ng/mL) and Brain (ng/g) Samples and the
Codeine/Morphine Ratios for Each Case





1 614 129 0.210 320 120 0.375
2 33 10 0.303 85 11 0.129
3 97 60 0.619 211 51 0.242
4 315 73 0.232 190 69 0.363
5 338 64 0.189 391 101 0.258
6 688 150 0.218 396 76 0.192
7 615 193 0.313 140 50 0.357
8 533 23 0.043 271 132 0.487
9 77 6 0.078 100 31 0.310
10 228 25 0.110 230 100 0.435
11 313 72 0.230 290 160 0.552
12 441 20 0.045 321 120 0.374
13 130 ,LOD – 87 31 0.356
14 171 ,LOD – 149 28 0.188
Figure 1. An overview of the analyte concentrations in the 14 blood (a) and brain tissue (b) samples. A comparison of the codeine/morphine ratios in blood and brain samples (c) is
also shown.
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Conclusions
We applied our validated method (16) to the determination of
morphine and codeine levels in brain (nuclei) tissue samples
from 14 fatal cases of suspected heroin overdose. The resulting
data were compared with the data obtained from blood samples,
which are usually used to establish the cause of death.
Regardless of the tissue analyzed, the cause of death could not
be conclusively determined from the isolated toxicological mea-
surements, although some ﬁrm inferences could be drawn. It is
an accepted belief that postmortem blood samples cannot be
used alone to determine the cause of death or signiﬁcant impair-
ment. Knowledge of the individual’s clinical history and the aut-
opsy ﬁndings must also be taken into account.
In our study, 14 cases were considered (Table I), and STAwas car-
ried out on all the available biological ﬂuids, which revealed the
concurrent use of other drugs of abuse, such as cocaine, metha-
done and benzodiazepines as well as the presence of cutting agents,
such as dextromethorphan and paracetamol. In all cases, morphine
was detected, indicating that the deaths may have been heroin
related. The concentrations of morphine and codeine (the pres-
ence of codeine being related to impure ‘street heroin’) were deter-
mined in blood and brain samples, and in the majority of cases, the
concentration of codeine was found to be higher in the brain than
in the blood. In particular, in cases 13 and 14, codeine was found
only in the brain and was not detected in the blood samples.
It is difﬁcult to interpret acute narcotism-related deaths on the
basis of chemical and toxicological data alone; however, in this
study, we attempted to elucidate the ratios between morphine
and codeine, and we found that the codeine-to-morphine ratio
was higher in the brain than in the blood in the majority of
cases (Figure 1C). A possible explanation for this phenomenon
may be the greater ability of codeine to reach the CNS due to
its higher lipophilicity (17).
In conclusion, we have found that codeine can accumulate in
the brain tissue of suspected heroin users; thus, its detection
within the brain could help determine the cause of death in sus-
pected overdose cases. On the basis of the results obtained in this
preliminary work, we are continuing to verify our assumptions by
determining and evaluating the concentrations of morphine and
codeine in the blood and brain tissues of a larger sample of her-
oin overdose fatalities.
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